[1] | K. Hanoch Kumar and P. Elavarasi, “Definition of pain and classification of pain disorders”, Journal of Advanced Clinical & Research Insights, vol. 3, no. 3, pp. 87-90, 2016. |
[2] | M. Aydede, “Defending the IASP definition of pain”, The Monist, vol. 100, no. 4, pp. 1-31, 2017. |
[3] | M. Cohen, J. Quintner, and S. van Rysewyk, “Reconsidering the International Association for the Study of Pain definition of pain”, PAIN Reports, vol. 3, no. 2, pp. e634, 2018. |
[4] | P. Brooks, “Issues with chronic musculoskeletal pain”, Rheumatology, vol. 44, no. 7, pp. 831-833, 2005. |
[5] | R-D. Treede, W. Rief, A. Barke, Q. Aziz, M. I. Bennett, R. Benoliel et al., “A classification of chronic pain for ICD-11”, Pain, vol. 156, no. 6, pp. 1003-1007, 2015. |
[6] | D. G. Borenstein, A. L. Hassett, and D. S. Pisetsky, “Pain management in rheumatology research, training, and practice”, Clinical and Experimental Rheumatology, vol. 35, no. 107, pp. S2-S7, 2017. |
[7] | M. A. Cimmino, C. Ferrone, and M. Cutolo, “Epidemiology of chronic musculoskeletal pain.”, Best Practice & Research. Clinical Rheumatology., vol. 25, no. 2, pp. 173-83, 2011. |
[8] | L. Vilen, A. R. Baldassari, and L. F. Callahan, “Socioeconomic burden of pain in rheumatic disease”, Clinical and Experimental Rheumatology, vol. 35, no. 107, pp. S26-S31, 2017. |
[9] | American College of Rheumatology Pain Management Task Force, “Report of the American College of Rheumatology Pain Management Task Force.”, Arthritis Care & Research, vol. 62, no. 5, pp. 590-9, 2010. |
[10] | P. H. Berry, C. R. Chapman, E. C. Covington, J. L. Dahl, J. A. Katz, C. Miaskowski et al., “Pain: Current Understanding of Assessment, Management, and Treatments”, National Pharmaceutical Council, Section IV: Management Of Acute Pain And Chronic Noncancer Pain, pp. 59-71, 2001. |
[11] | Q. Xu and T. L. Yaksh, “A brief comparison of the pathophysiology of inflammatory versus neuropathic pain.”, Current Opinion in Anaesthesiology, vol. 24, no. 4, pp. 400-7, 2011. |
[12] | K. Phillips and D. J. Clauw, “Central Pain Mechanisms in Rheumatic Diseases: Future directions”, Arthritis Rheumatology, vol. 65, no. 2, pp. 291-302, 2013. |
[13] | S. A. Schug, G. M. Palmer, D. A. Scott, R. Halliwell, and J. Trinca, “Acute pain management: scientific evidence, fourth edition, 2015.”, The Medical Journal of Australia, vol. 204, no. 8, pp. 315-7, 2016. |
[14] | I. Gilron, R. Baron, and T. Jensen, “Neuropathic Pain: Principles of Diagnosis and Treatment”, Mayo Clinic Proceedings, vol. 90, no. 4, pp. 532-545, 2015. |
[15] | L. Leung and C. M. Cahill, “TNF-α and neuropathic pain - a review”, Journal of Neuroinflammation, vol. 7, no. 4, pp. 27, 2010. |
[16] | S. P. Cohen and J. Mao, “Neuropathic pain: mechanisms and their clinical implications.”, BMJ , vol. 348, f1756, 2014. |
[17] | C. Voscopoulos and M. Lema, “When does acute pain become chronic?”, British Journal of Anaesthesia, vol. 105, no. 1, pp. i69-85, 2010. |
[18] | P. Schweinhardt and M. C. Bushnell, “Pain imaging in health and disease — how far have we come?”, The Journal of Clinical Investigation, vol. 120, no. 11, pp. 3788-3797, 2010. |
[19] | J. W. Vlaeyen and S. J. Linton, “Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art.”, Pain, vol. 85, no. 3, pp. 317-32, 2000. |
[20] | C. E. Steeds, “The anatomy and physiology of pain”, Surgery, vol. 31, no. 2, pp. 49-53, 2013. |
[21] | A. Koneru, S. Satyanarayana, and S. Rizwan, “Endogenous Opioids: Their Physiological Role and Receptors”, Global Journal of Pharmacology, vol. 3, no. 3, pp. 149-153, 2009. |
[22] | R. Al-Hasani and M. R. Bruchas, “Molecular mechanisms of opioid receptor-dependent signaling and behavior.”, Anesthesiology, vol. 115, no. 6, pp. 1363-1381, 2011. |
[23] | Y. Bao, Y. Gao, L. Yang, X. Kong, J. Yu, W. Hou et al., “The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence”, Channels, vol. 9, no. 5, pp. 235-243, 2015. |
[24] | I. Tracey and P. W. Mantyh, “The cerebral signature for pain perception and its modulation.”, Neuron, vol. 55, no. 3, pp. 377-91, 2007. |
[25] | M. H. Ossipov, G. O. Dussor, and F. Porreca, “Central modulation of pain.”, The Journal of Clinical Investigation, vol. 120, no. 11, pp. 3779-87, 2010. |
[26] | F. Amaya, Y. Izumi, M. Matsuda, and M. Sasaki, “Tissue injury and related mediators of pain exacerbation.”, Current Neuropharmacology, vol. 11, no. 6, pp. 592-597, 2013. |
[27] | G. Santoni, C. Cardinali, M. B. Morelli, M. Santoni, M. Nabissi, and C. Amantini, “Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons.”, Journal of Neuroinflammation, vol. 12, 21, 2015. |
[28] | A. D. Cook, A. D. Christensen, D. Tewari, S. B. McMahon, and J. A. Hamilton, “Immune Cytokines and Their Receptors in Inflammatory Pain.”, Trends in Immunology, vol. 39, no. 3, pp. 240-255, 2018. |
[29] | H. G. Schaible, “Nociceptive neurons detect cytokines in arthritis”, Arthritis Research & Therapy, vol. 16, no. 5, pp. 470, 2014. |
[30] | M. E. Costello, D. Elewaut, T. J. Kenna, and M. A. Brown, “Microbes, the gut and ankylosing spondylitis.”, Arthritis Research & Therapy, vol. 15, no. 3, pp. 214-254, 2013. |
[31] | M. W. Teng, E. P. Bowman, J. J. McElwee, M. J. Smyth, J. L. Casanova, A. M. Cooper et al., “IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.”, Nature Medicine, vol. 21, no. 7, pp. 719-29, 2015. |
[32] | Y. Okamura, S. Mishima, J. Kashiwakura, T. Sasaki-Sakamoto, S. Toyoshima, K. Kuroda et al., “The dual regulation of substance P-mediated inflammation via human synovial mast cells in rheumatoid arthritis”, Allergology International, vol. 66, no. 9, pp. S9-S20, 2017. |
[33] | M. E. Walker, J. K. Hatfield, and M. A. Brown, “New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?”, Biochimica Et Biophysica Acta, vol. 1822, no. 1, pp. 57-65, 2012. |
[34] | Y. Q. Zhou, Z. Liu, Z. H. Liu, S. P. Chen, M. Li, A. Shahveranov et al., “Interleukin-6: an emerging regulator of pathological pain.”, Journal of Neuroinflammation, vol. 13, no. 1, pp. 141-50, 2016. |
[35] | Z. Guan, J. Hellman, and M. Schumacher, “Contemporary views on inflammatory pain mechanisms: TRPing over innate and microglial pathways”, F1000Research, vol. 5, (F1000 Faculty Rev), no. 9, pp. 2425, 2016. |
[36] | R. R. Ji, Z. Z. Xu, and Y. J. Gao, “Emerging targets in neuroinflammation-driven chronic pain.”, Nature Reviews. Drug Discovery., vol. 13, no. 7, pp. 533-48, 2014. |
[37] | D. R. Kirkpatrick, D. M. McEntire, Z. J. Hambsch, M. J. Kerfeld, T. A. Smith, M. D. Reisbig et al., “Therapeutic Basis of Clinical Pain Modulation”, Clinical and Translational Science, vol. 8, no. 6, pp. 848-856, 2015. |
[38] | R. Taylor Jr., S. Lemtouni, K. Weiss, and J. V. Pergolizzi, “Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel’s View on Preventable Harm Associated with NSAID Therapy”, Current Gerontology and Geriatrics Research, vol. 2012, Article ID 196159, 9 pages, 2012. |
[39] | F. Rannou, J. P. Pelletier, and J. Martel-Pelletier, “Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys.”, Seminars in Arthritis and Rheumatism, vol. 45, no. 4, pp. S18-21, 2016. |
[40] | S. Haroutiunian, D. A. Drennan, and A. G. Lipman, “Topical NSAID therapy for musculoskeletal pain.”, Pain Medicine (Malden, Mass.), vol. 11, no. 4, pp. 535-49, 2010. |
[41] | Y. Higashi, T. Kiuchi, and K. Furuta, “Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study.”, Clinical Therapeutics, vol. 32, no. 1, pp. 34-43, 2010. |
[42] | I. Sekiya, T. Morito, K. Hara, J. Yamazaki, Y. J. Ju, K. Yagishita et al., “Ketoprofen absorption by muscle and tendon after topical or oral administration in patients undergoing anterior cruciate ligament reconstruction.”, AAPS PharmSciTech., vol. 11, no. 1, pp. 154-8, 2010. |
[43] | B. Liu, L. Fan, S. Balakrishna, A. Sui, J. B. Morris, and S. E. Jordt, “TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain.”, Pain, vol. 154, no. 10, pp. 2169-77, 2013. |
[44] | J. V. Pergolizzi Jr., R. Taylor Jr., J. A. LeQuang, R. B. Raffa, and NEMA Research Group, “The role and mechanism of action of menthol in topical analgesic products.”, Journal of Clinical Pharmacy and Therapeutics, vol. 43, no. 3, pp. 313-319, 2018. |
[45] | C. Abdel Shaheed, C. G. Maher, K. A. Williams, and A. J. McLachlan, “Interventions available over the counter and advice for acute low back pain: systematic review and meta-analysis.”, The Journal of Pain, vol. 15, no. 1, pp. 2-15, 2014. |
[46] | R. Chou, R. Deyo, J. Friedly, A. Skelly, M. Weimer, R. Fu et al., “Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.”, Annals of Internal Medicine, vol. 166, no. 7, pp. 480-492, 2017. |
[47] | A. M. Trescot, S. Datta, M. Lee, and H. Hansen, “Opioid pharmacology.”, Pain Physician, vol. 11, no. 2, pp. S133-53, 2008. |
[48] | A. Goebel, “Complex regional pain syndrome in adults”, Rheumatology, vol. 50, no. 10, pp. 1739-1750, 2011. |
[49] | B. Lisowska, D. Kosson, K. Domaracka, “Positives and negatives of nonsteroidal anti-inflammatory drugs in bone healing: the effects of these drugs on bone repair”, Drug Design, Development and Therapy, vol. 12, pp. 1809-1814, 2018. |
[50] | T. Markovic, Z. Jakopin, M. Sollner Dolenc, and I. Mlinari-Rascan, “Structural features of subtype-selective EP receptor modulators”, Drug Discovery Today, vol. 22, no. 1, pp. 57-71, 2017. |
[51] | M. C. van der Goes, J. W. Jacobs, and J. W. Bijlsma, “The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects”, Arthritis Research & Therapy, vol. 16, suppl. 2, pp. S2-S15, 2014. |
[52] | D. M. Schwartz, M. Bonelli, M. Gadina, and J. J. O’Shea, “Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.”, Nature Reviews. Rheumatology., vol. 12, no. 1, pp. 25-36, 2016. |
[53] | M. Sergeeva, J. Rech, G. Schett, and A. Hess, “Response to peripheral immune stimulation within the brain: magnetic resonance imaging perspective of treatment success.”, Arthritis Research & Therapy, vol. 17, 268, 2015. |
[54] | P. C. Taylor, R. Fleischmann, E. Perkins, J. Lisse, B. Zhu, C. L. Gaich et al., “Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo”, Arthritis Rheumatology, vol. 69, suppl 10, 2017. |
[55] | B. N. Cronstein and P. Sunkureddi, “Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.”, Journal of Clinical Rheumatology: practical reports on rheumatic & musculoskeletal diseases., vol. 19, no. 1, pp. 19-29, 2013. |
[56] | C. Birbara, E. J. Dabezies, A. M. JR. Burr, R. J. Fountaine, M. D. Smith, M. T. Brown et al., “Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis”, Journal of Pain Research, vol. 11, no. 1, pp. 151-164, 2018. |
[57] | A. R. Tso and P. J. Goadsby, “Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?”, Current Treatment Options in Neurology, vol. 19, no. 8, pp. 27, 2017. |
[58] | R. Geenen, C. L. Overman, R. Christensen, P. Åsenlöf, S. Capela, K. L. Huisinga et al., “EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis.”, Annals of the Rheumatic Diseases, vol. 77, no. 6, pp. 797-807, 2018. |
[59] | R. D. Blondell, M. Azadfard, and A. M. Wisniewski, “Pharmacologic therapy for acute pain.”, American Family Physician, vol. 87, no. 11, pp. 766-772, 2013. |
[60] | Institute for Clinical Systems Improvement, “Health Care Guideline: Assessment and Management of Chronic Pain”, Institute for Clinical Systems Improvement, www.icsi.org, vol. First Edition, November 2005, pp. 2-78, 2005. |
[61] | P. G. Fine, “Treatment guidelines for the pharmacological management of pain in older persons.”, Pain medicine (Malden, Mass.), vol. 13, no. 2, pp. S57-S66, 2012. |
[62] | R. H. Dworkin, A. B. O’Connor, J. Audette, R. Baron, G. K. Gourlay, M. L. Haanpää et al., “Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update”, Mayo Clinic Proceedings, vol. 85, no. 3, pp. S3-S14, 2010. |
[63] | K. Sinusas, “Osteoarthritis: diagnosis and treatment.”, American Family Physician, vol. 85, no. 1, pp. 49-56, 2012. |
[64] | M. C. Hochberg, R. D. Altman, K. T. April, M. Benkhalti, G. Guyatt, J. McGowan et al., “American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.”, Arthritis Care & Research, vol. 64, no. 4, pp. 465-474, 2012. |
[65] | T. E. McAlindon, R. R. Bannuru, M. C. Sullivan, N. K. Arden, F. Berenbaum, S. M. Bierma-Zeinstra et al., “OARSI guidelines for the non-surgical management of knee osteoarthritis.”, Osteoarthritis and Cartilage, vol. 22, no. 3, pp. 363-388, 2014. |
[66] | NICE clinical guideline, “Osteoarthritis: care and management”, guidance.nice.org.uk/cg177, 2014. |
[67] | O. Bruyère, R. D. Altman, and J. Y. Reginster, “Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.”, Seminars in Arthritis and Rheumatism, vol. 45, no. 4, pp. S12-S17, 2016. |
[68] | A. Quaseem, T. J. Wilt, R. M. McLean, M. A. Forciea, Clinical Guidelines Committee of the American College of Physicians, “Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.”, Annals of Internal Medicine, vol. 166, no. 7, pp. 514-530, 2017. |
[69] | J. Nijs, A. Apeldoorn, H. Hallegraeff, J. Clark, R. Smeets, A. Malfliet et al, “Low Back Pain: Guidelines for the Clinical Classification of Predominant Neuropathic, Nociceptive, or Central Sensitization Pain”, Pain Physician, vol. 18, pp. E333-E346, 2015. |